| 1 |
NCT00897702 |
Recruiting |
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer |
|
- Other: Blood draw
- Other: immunoenzyme technique
- Procedure: biopsy
- Procedure: histopathologic examination
|
Observational |
|
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
- Memorial Sloan Kettering Cancer Center
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- To look for mutations in druggable oncogenic pathways in tumors progressing on anti-HER2 therapy or hormonal therapy
- To characterize the activity of the PI3K signaling pathway in progressive breast tumors using proteomic methods
- To develop new laboratory models of treatment refractory breast cancer from human tumor specimens
- (and 3 more...)
|
400 |
All |
Child, Adult, Senior |
NCT00897702 |
06-163
MSKCC-06163 |
|
January 9, 2007 |
January 2019 |
January 2019 |
May 12, 2009 |
December 15, 2017 |
|
- Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States - (and 3 more...)
|
| 2 |
NCT02753686 |
Recruiting |
Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy |
- HR+ HER2- Postmenopausal Advanced Breast Cancer
|
- Drug: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant
- Drug: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
|
Observational |
|
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Duration on Treatment
- Number of participants with adverse events in ET and ET+TT cohorts
- Time to Treatment Failure (TTF)
- (and 6 more...)
|
320 |
Female |
18 Years and older (Adult, Senior) |
NCT02753686 |
CRAD001YCA09 |
Treat ER+ight |
March 15, 2016 |
December 2, 2019 |
December 2, 2019 |
April 28, 2016 |
February 7, 2018 |
|
- Novartis Investigative Site
Burnaby, British Columbia, Canada - Novartis Investigative Site
Richmond, British Columbia, Canada - Novartis Investigative Site
Vancouver, British Columbia, Canada - (and 14 more...)
|
| 3 |
NCT02988648 |
Recruiting |
A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter |
|
- Radiation: Radioiodide (131I-)
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- objective tumor response rate
|
37 |
Female |
18 Years to 70 Years (Adult, Senior) |
NCT02988648 |
1607018035 |
|
December 2016 |
August 2019 |
August 2019 |
December 9, 2016 |
January 9, 2018 |
|
- Smilow Cancer Center
New Haven, Connecticut, United States
|
| 4 |
NCT01904903 |
Recruiting |
Cardiac Safety Study in Patients With HER2 + Breast Cancer |
- HER2 Positive Breast Cancer
- Left Ventricular Function Systolic Dysfunction
|
- Drug: Trastuzumab, Pertuzumab, Ado-trastuzumab emtansine
|
Interventional |
Phase 2 |
- Washington Hospital Center
- Genentech, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients who complete planned oncologic therapy without the development of a cardiac event or asymptomatic worsening of cardiac function.
- Median time to development of an event defined as cardiac event or asymptomatic worsening of left ventricular dysfunction, among patients who developed one event.
- Absolute changes in LVEF during HER2 targeted therapy
- (and 3 more...)
|
30 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT01904903 |
ML 28685 |
SAFE-HEaRt |
August 2013 |
August 2017 |
August 2018 |
July 22, 2013 |
December 9, 2015 |
|
- Washington Cancer Institute at MedStar Washington Hospital Center
Washington, District of Columbia, United States - MedStar Georgetown University Hospital
Washington, District of Columbia, United States
|
| 5 |
NCT02286843 |
Recruiting |
Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy? |
- Breast Cancer Metastases
- HER2 Positive Breast
|
- Radiation: 89Zr-trastuzumab
- Device: PET/CT scan
- Radiation: 89Zr-pertuzumab
|
Interventional |
Not Applicable |
- Memorial Sloan Kettering Cancer Center
- United States Department of Defense
- Genentech, Inc.
- Memorial Sloan Kettering Cancer Center
|
Other / U.S. Fed / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- proportion of patients with HER2- primary breast cancer who develop imagable HER2+ metastases
|
50 |
Female |
18 Years and older (Adult, Senior) |
NCT02286843 |
14-156 |
|
November 2014 |
November 2018 |
November 2018 |
November 10, 2014 |
December 20, 2017 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 6 |
NCT02597179 |
Recruiting |
Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of Participants With Mutated Genes and/or Abnormal Gene expression and/or Different Immune signature That Affect to Treatment Outcome.
|
350 |
All |
21 Years and older (Adult, Senior) |
NCT02597179 |
2012-08-065 |
|
September 2012 |
July 2018 |
July 2019 |
November 5, 2015 |
May 1, 2017 |
|
- Samsung Medical Center
Seoul, Gangnam-Gu, Korea, Republic of
|
| 7 |
NCT03006172 |
Recruiting |
To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer |
|
- Drug: GDC-0077
- Drug: Fulvestrant
- Drug: Letrozole
- Drug: Palbociclib
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Stage 1: Percentage of Participants With Dose Limiting Toxicities
- Recommended Phase II Dose of GDC-0077
- Percentage of Participants With Adverse Events and Serious Adverse Events
- (and 19 more...)
|
156 |
All |
18 Years and older (Adult, Senior) |
NCT03006172 |
GO39374
2016-003022-17 |
|
November 30, 2016 |
February 29, 2020 |
February 29, 2020 |
December 30, 2016 |
December 14, 2017 |
|
- Massachusetts General Hospital.
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States - Columbia University Medical Center
New York, New York, United States - (and 9 more...)
|
| 8 |
NCT02470819 |
Recruiting |
Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer |
- Metastatic Breast Cancer
- Breast Tumor
- Advanced Gynecologic Cancer
|
- Genetic: Genetic profiling
|
Interventional |
Not Applicable |
- Avera McKennan Hospital & University Health Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Tumor assessment
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT02470819 |
AMEM-2014-DOD001 |
|
March 2014 |
December 31, 2019 |
December 31, 2020 |
June 12, 2015 |
August 7, 2017 |
|
- Avera Cancer Institute
Sioux Falls, South Dakota, United States
|
| 9 |
NCT02344472 |
Recruiting |
Detect V / CHEVENDO (Chemo vs. Endo) |
|
- Drug: pertuzumab
- Drug: Trastuzumab
- Drug: Capecitabine
- (and 8 more...)
|
Interventional |
Phase 3 |
- Prof. W. Janni
- Roche Pharma AG
- DETECT study group
- University of Ulm
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events
- quality-adjusted survival
- overall response rate (ORR)
- (and 7 more...)
|
270 |
Female |
18 Years and older (Adult, Senior) |
NCT02344472 |
D-V
2014-002249-22 |
|
September 2015 |
September 2021 |
September 2021 |
January 26, 2015 |
June 7, 2017 |
|
- University Hospital Ulm Gynecology/Obstetrics
Ulm, Germany
|
| 10 |
NCT02947685 |
Recruiting |
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer |
- HER-2 Positive Breast Cancer
- Estrogen Receptor Positive Breast Cancer
|
- Drug: palbociclib
- Drug: trastuzumab
- Drug: pertuzumab
- (and 4 more...)
|
Interventional |
Phase 3 |
- Alliance Foundation Trials, LLC.
- Pfizer
- German Breast Group
- (and 10 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS) as assessed by Investigator
- Overall Survival (OS)
- 3 and 5 year survival probabilities
- (and 5 more...)
|
496 |
All |
18 Years and older (Adult, Senior) |
NCT02947685 |
AFT-38 |
PATINA |
June 21, 2017 |
October 31, 2020 |
August 31, 2024 |
October 28, 2016 |
April 12, 2018 |
|
- Southern Cancer Center
Mobile, Alabama, United States - Mayo Clinic, AZ
Phoenix, Arizona, United States - UCSF
San Francisco, California, United States - (and 53 more...)
|
| 11 |
NCT02963363 |
Recruiting |
Adapted Physical Activity for Breast Cancer HER2 Positive Patient |
- HER2 Positive Breast Cancer
|
- Other: Home-based Adapted Physical Activity
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Rate of patients reaching international physical activity recommendations for post-neoadjuvant chemotherapy assessment
- Longitudinal evolution of RPAQ score
- Quality of life : Quality of Life Questionnaire-C30
- (and 9 more...)
|
70 |
Female |
18 Years and older (Adult, Senior) |
NCT02963363 |
2016-A01344-47 |
APACAN2 |
February 27, 2018 |
February 2020 |
February 2020 |
November 15, 2016 |
March 13, 2018 |
|
- Centre Jean Perrin
Clermont-Ferrand, France
|
| 12 |
NCT03182634 |
Recruiting |
The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial |
|
- Drug: Fulvestrant
- Drug: Neratinib
- Drug: AZD5363
|
Interventional |
Phase 2 |
- Institute of Cancer Research, United Kingdom
- Royal Marsden NHS Foundation Trust
- Institute of Cancer Research, United Kingdom
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- The primary endpoint for Cohorts A to D is confirmed objective response rate as defined by RECIST v1.1 for each cohort separately
- Clinical benefit rate
- Progression free survival
- (and 7 more...)
|
1000 |
Female |
18 Years and older (Adult, Senior) |
NCT03182634 |
ICR-CTSU/2015/10056 |
plasmaMATCH |
December 15, 2016 |
November 2022 |
November 2023 |
June 9, 2017 |
June 12, 2017 |
|
- Royal Marsden Hosital, Sutton
Surrey, England, United Kingdom - Royal Bournemouth Hospital
Bournemouth, United Kingdom - Addenbrooke's Hospital
Cambridge, United Kingdom - (and 5 more...)
|
| 13 |
NCT03321045 |
Recruiting |
PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness |
|
- Drug: [89Zr]-Df-Trastuzumab
- Diagnostic Test: PET/MRI Imaging
|
Interventional |
Early Phase 1 |
- University of Alabama at Birmingham
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Investigate the use of [89Zr]-Df-Trastuzumab as a HER2 imaging agent
|
10 |
Female |
18 Years and older (Adult, Senior) |
NCT03321045 |
IRB-170220004 |
|
November 21, 2017 |
January 2022 |
January 2022 |
October 25, 2017 |
January 23, 2018 |
|
- The Kirklin Clinic
Birmingham, Alabama, United States
|
| 14 |
NCT02409316 |
Recruiting |
[18F]FES PET/CT in Endocrine Refractory Breast Cancer |
- Estrogen Receptor Positive Breast Cancer
- Breast Neoplasm
- Metastatic Breast Cancer
|
|
Interventional |
Phase 2 |
- University of Pennsylvania
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Evaluate [18F]FES PET/CT uptake as a predictor of progression free survival in endocrine refractory recurrent or metastatic breast cancer patients starting a new therapy regimen including endocrine targeted therapy
- Correlate [18F]FES uptake measures with standard immunohistochemistry (IHC) (e.g. ER, PR, HER2-neu) and experimental pathology markers available from primary and/or metastatic tissue
- Evaluate the utility of combined [18F]FES PET/CT and FDG PET/CT in identifying heterogeneity of estrogen receptor expression and functionality in metastatic breast cancer
- (and 3 more...)
|
75 |
Female |
18 Years and older (Adult, Senior) |
NCT02409316 |
821717 |
|
May 2015 |
May 2019 |
May 2019 |
April 6, 2015 |
October 4, 2017 |
|
- University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
|
| 15 |
NCT03323424 |
Not yet recruiting |
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers |
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
- Metastatic Head and Neck Cancer
|
- Radiation: Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)
- Other: Systemic treatment
|
Interventional |
Phase 2 |
- Institut de Cancérologie de la Loire
- Saint-Louis Hospital, Paris, France
- Gustave Roussy Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival rate without progression for patients with metastatic breast cancer
- Survival rate without progression for metastatic head and neck cancer
- Survival rate without progression for patients with metastatic colorectal cancer
- (and 5 more...)
|
207 |
All |
18 Years and older (Adult, Senior) |
NCT03323424 |
2017-0301
2017-A02043-50 |
IRAM |
November 1, 2017 |
October 31, 2024 |
October 31, 2024 |
October 27, 2017 |
October 27, 2017 |
|
- Clinique Claude Bernard
Albi, France - Centre Léonard de Vinci
Dechy, France - Centre Hospitalier Privé Saint Gregoire
Saint-Grégoire, France - (and 3 more...)
|
| 16 |
NCT03243838 |
Not yet recruiting |
Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer |
- Triple-Negative Breast Cancer
|
|
Interventional |
Phase 1
Phase 2 |
- Guangdong General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
40 |
Female |
18 Years to 70 Years (Adult, Senior) |
NCT03243838 |
20170328 |
LANCET |
April 2, 2018 |
December 30, 2019 |
December 30, 2019 |
August 9, 2017 |
February 6, 2018 |
|
- Guangdong general hospital
Guangzhou, Guangdong, China
|
| 17 |
NCT02559544 |
Recruiting |
[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo Estrogen Receptor Activity in Endocrine Refractory Recurrent or Metastatic Breast Cancer |
- Recurrent ER+ Breast Cancer
- Metastatic ER+ Breast Cancer
|
- Radiation: [18F]Fluoroestradiol (FES) PET/CT Imaging
|
Interventional |
Not Applicable |
- Abramson Cancer Center of the University of Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02559544 |
UPCC 20114 |
|
May 2015 |
May 2019 |
May 2019 |
September 24, 2015 |
July 31, 2017 |
|
- Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 18 |
NCT03197805 |
Recruiting |
Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients |
|
- Diagnostic Test: PAM 50 test
|
Interventional |
Not Applicable |
- Centre Jean Perrin
- Roche Pharma AG
- NanoString Technologies, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The modification of therapeutical decision between the first and the second multidisciplinary decision-making meeting (MD-MM) using a genomic testing
- The HER2 overexpression incidence according to RNA genomic profile among equivocal-HER2 patients
- The concordance between the second multidisciplinary decision-making meeting decision and the HER2 genomic test result
|
260 |
Female |
18 Years and older (Adult, Senior) |
NCT03197805 |
2017-A00240-53 |
EQUIVOK |
October 16, 2017 |
March 2019 |
April 2019 |
June 23, 2017 |
October 26, 2017 |
|
- CHRU Jean Minoz
Besançon, France - Institut Bergonie
Bordeaux, France - Centre François Baclesse
Caen, France - (and 14 more...)
|
| 19 |
NCT02856503 |
Recruiting |
Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors |
- Breast Cancer
- Invasive Breast Carcinoma
- Ductal Carcinoma In-situ
|
|
Interventional |
Phase 1
Phase 2 |
- Eli Avisar
- University of Miami
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1 - Rate of Treatment-Related Toxicity in Subjects
- Phase 2 - Rate of Favorable Treatment Response in Subjects Receiving Protocol Therapy Given Within the Optimal Duration Determined in Phase 1.
- Phase 1 - Optimal Duration of Once-Weekly Protocol Therapy
- Phase 2 - Rate of Treatment-Related Toxicity in Subjects
|
44 |
Female |
18 Years and older (Adult, Senior) |
NCT02856503 |
20150288 |
|
July 2018 |
July 2022 |
July 2023 |
August 5, 2016 |
February 22, 2018 |
|
- University of Miami
Miami, Florida, United States
|
| 20 |
NCT03168880 |
Recruiting |
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer |
- Triple Negative Breast Cancer
|
- Drug: Paclitaxel + Carboplatin
- Drug: Paclitaxel only
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
720 |
Female |
18 Years to 70 Years (Adult, Senior) |
NCT03168880 |
CTRI/2012/07/002802 |
TNBC |
April 2010 |
November 30, 2019 |
November 30, 2024 |
May 30, 2017 |
May 30, 2017 |
|
- Tata memorial Centre
Mumbai, Maharashtra, India
|
| 21 |
NCT01781338 |
Recruiting |
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer |
|
|
Interventional |
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Identification of a responder sub-population with intermediate and high risk, which due to therapy has outcome comparable to HR+/RS≤11
- Overall survival
|
4936 |
Female |
18 Years to 75 Years (Adult, Senior) |
NCT01781338 |
WSG-AM06 / ADAPT |
ADAPT |
May 2012 |
April 2020 |
|
February 1, 2013 |
May 19, 2015 |
|
- Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern
Munich, Bavaria, Germany - Ev. Krankenhaus Bethesda Brustzentrum Niederrhein
Moenchengladbach, NRW, Germany
|
| 22 |
NCT02500199 |
Recruiting |
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors |
- Breast Cancer
- Gastric Cancer
- Solid Tumors
- NSCLC
|
|
Interventional |
Phase 1 |
- Hengrui Therapeutics, Inc.
- Hengrui Therapeutics, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Part 1 Maximum Tolerated Dose (MTD)
- Part 2 Overall Response Rate (ORR)
- Maximum plasma concentration(Cmax)
- (and 6 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02500199 |
SHRUS 1001 |
|
June 2015 |
December 2019 |
March 2020 |
July 16, 2015 |
February 21, 2018 |
|
- Florida Cancer Specialists
Sarasota, Florida, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - (and 5 more...)
|
| 23 |
NCT01619111 |
Recruiting |
DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs |
- HER2-negative Metastatic Breast Cancer
- HER2-positive Circulating Tumor Cells
|
- Drug: standard chemo- or endocrine therapy
- Drug: standard chemo- or endocrine therapy + Lapatinib
|
Interventional |
Phase 3 |
- Prof. W. Janni
- University of Ulm
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CTC clearance rate
- Overall response rate
- Clinical benefit rate
- (and 7 more...)
|
120 |
Female |
18 Years and older (Adult, Senior) |
NCT01619111 |
DETECT III
2010-024238-46 |
DETECT III |
February 2012 |
March 2018 |
March 2020 |
June 14, 2012 |
June 7, 2017 |
|
- University Hospital Ulm
Ulm, Baden-Württemberg, Germany
|
| 24 |
NCT01503905 |
Recruiting |
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients |
- Breast Cancer Nos Premenopausal
|
- Drug: Docetaxel
- Drug: epirubicin
- Drug: cyclophosphamide
- (and 7 more...)
|
Interventional |
Not Applicable |
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival of patients.
- Overall survival of the patients
- The pathological remission rate of patients after neoadjuvant chemotherapy.
- The clinical remission rate of patients after neoadjuvant chemotherapy
|
600 |
Female |
18 Years and older (Adult, Senior) |
NCT01503905 |
BCSCO001 |
|
December 2011 |
May 2018 |
December 2021 |
January 4, 2012 |
May 24, 2016 |
|
- The first People's Hospital of Foshan
Foshan, Guangdong, China - Guangdong Women and Children Hospital
Guangzhou, Guangdong, China - Guangzhou Army General Hospital
Guangzhou, Guangdong, China - (and 14 more...)
|
| 25 |
NCT02871791 |
Recruiting |
Palbociclib With Everolimus + Exemestane In BC |
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Hormone Receptor (HR)-Positive Breast Cancer
|
- Drug: Palbociclib
- Drug: Everolimus
- Drug: Exemestane
|
Interventional |
Phase 1
Phase 2 |
- Dana-Farber Cancer Institute
- Pfizer
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with Dose-Limiting Toxicities (DLT)
- Clinical Benefit Rate
- Overall Response Rate
- (and 3 more...)
|
32 |
All |
18 Years and older (Adult, Senior) |
NCT02871791 |
16-177 |
|
August 24, 2016 |
October 2019 |
July 2021 |
August 18, 2016 |
March 27, 2017 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 26 |
NCT03332368 |
Recruiting |
Clinical Study on Triple Negative Breast Cancer With Chinese Medicine |
- Progression-Free-Survival
- Recurrence
- Overall Survival
|
- Other: Traditional Chinese medicine
|
Observational |
|
- Sheng Liu
- Longhua Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progression-Free-Survival, PFS
- Overall Survival，OS
- TCM Symptom Scale
- (and 3 more...)
|
620 |
Female |
18 Years to 75 Years (Adult, Senior) |
NCT03332368 |
LonghuaH(TNBC)
Special Research on TCM |
|
January 1, 2017 |
January 1, 2019 |
January 1, 2019 |
November 6, 2017 |
November 7, 2017 |
|
- Fudan University Cancer Hospital
Shanghai, Shanghai, China - Longhua Hosptial
Shanghai, Shanghai, China - ShuGuang Hospital
Shanghai, Shanghai, China - (and 2 more...)
|
| 27 |
NCT02626039 |
Recruiting |
Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients |
|
|
Observational |
|
- Hospital General Universitario Gregorio Marañon
|
Other |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Cohen's kappa coefficient to measure the inter-rater agreement for mutations and other genomic findings (categorical items) between the metastatic tissue and the primary tumor tissue in Metastatic Breast Cancer patients.
- Number of somatic genomic findings (found in the primary and metastatic tumor) in circulating tumoral cells (CTC) and circulating free DNA(cfDNA) obtained from peripheral blood (liquid biopsy).
- Description of the mutations in analyzed genes in the primary tumor and in CTC/cfDNA for each patient.
|
40 |
Female |
18 Years and older (Adult, Senior) |
NCT02626039 |
GOMHGUGM092013 |
MIRROR |
November 2013 |
March 2017 |
April 2017 |
December 10, 2015 |
March 9, 2017 |
|
- Hospital General Universitario Gregorio Marañón
Madrid, Spain
|
| 28 |
NCT03289819 |
Not yet recruiting |
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC |
- Malignant Neoplasm of Breast
|
- Drug: Pembrolizumab
- Drug: nab-paclitaxel
- Drug: Epirubicin
- Drug: Cyclophosphamide
|
Interventional |
Phase 2 |
- Institut fuer Frauengesundheit
- Merck Sharp & Dohme Corp.
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathological Complete Response (pCR) rate
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Clinical Response
- (and 2 more...)
|
50 |
Female |
18 Years and older (Adult, Senior) |
NCT03289819 |
IFG-NIB-01
2016-003102-14
U1111-1188-3915 |
NIB |
October 2017 |
November 2018 |
December 2018 |
September 21, 2017 |
September 21, 2017 |
|
- Department of Gynecology and Obstetrics, Erlangen University Hospital
Erlangen, Bavaria, Germany
|
| 29 |
NCT03089502 |
Recruiting |
Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity |
- Breast Cancer
- Left Ventricular Dysfunction
- Heart Failure, Systolic
|
- Other: Exercise Rehabilitation
|
Interventional |
Not Applicable |
- University Health Network, Toronto
- MSH-UHN AMO Innovation Fund
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Cardiopulmonary Fitness
- Cardiovascular Risk Profile
- Cardiac Function and Structure at Rest
- (and 5 more...)
|
38 |
Female |
18 Years and older (Adult, Senior) |
NCT03089502 |
CORE |
CORE |
November 1, 2017 |
December 1, 2018 |
April 1, 2019 |
March 24, 2017 |
October 30, 2017 |
|
- Toronto Rehabilitation Institute
Toronto, Ontario, Canada
|
| 30 |
NCT02062489 |
Recruiting |
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients |
|
- Drug: Tamoxifen
- Drug: Placebo
|
Interventional |
Phase 4 |
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Disease-free survival of patients
- Rates of adverse reactions
- Distant metastasis-free survival
- Overall survival
|
688 |
Female |
18 Years to 65 Years (Adult) |
NCT02062489 |
BCCT2014001 |
|
May 2014 |
May 2023 |
May 2024 |
February 13, 2014 |
April 17, 2018 |
|
- The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China - The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China - Guangdong Women and Children Hospital
Guangzhou, Guangdong, China - (and 6 more...)
|
| 31 |
NCT02338167 |
Recruiting |
Praegnant Breast Cancer |
|
- Procedure: Blood sampling
|
Observational |
|
- University Hospital Tuebingen
|
Other |
- Observational Model: Case-Only
- Time Perspective: Other
|
- Discovery of biomarkers, which predict progression free survival (PFS)
- Assessment of overall survival (OS)
- Assessment of breast cancer specific survival (BCSS)
- (and 10 more...)
|
3500 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02338167 |
SEN-01/14 |
PRAEGNANT |
June 2014 |
June 2018 |
|
January 14, 2015 |
August 25, 2017 |
|
- Klinik für Frauenheilkunde, Universitätsklinikum Freiburg
Freiburg, Baden-Württemberg, Germany - NCT Heidelberg
Heidelberg, Baden-Württemberg, Germany - Frauenklinik der St. Vincentius-Kliniken gAG
Karlsruhe, Baden-Württemberg, Germany - (and 55 more...)
|
| 32 |
NCT02850302 |
Recruiting |
Triple Negative Breast Cancer: Identification Pilot Study of Predictive Transcriptome Profiles of Early Tumor Drug Resistance Observed in 18F-Fluorodeoxyglucose (FDG) PET |
|
- Other: PET with FDG
- Other: Tumor exome analysis
|
Interventional |
Not Applicable |
- Centre Georges Francois Leclerc
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Variation of mutational profile
|
20 |
Female |
18 Years to 90 Years (Adult, Senior) |
NCT02850302 |
TRANSTEP |
TRANSTEP |
November 2016 |
May 2018 |
November 2023 |
August 1, 2016 |
June 21, 2017 |
|
|
| 33 |
NCT02642406 |
Recruiting |
Therapy Management With Nab-Paclitaxel in Daily Routine |
|
- Procedure: Blood sampling
|
Observational |
|
- University Hospital Tuebingen
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Epidemiological assessment of progression free survival (PFS) under real life conditions.
- Assessment of overall survival ()OS.
- Influence of age on the prognosis and quality of life.
- (and 5 more...)
|
1200 |
Female |
18 Years to 99 Years (Adult, Senior) |
NCT02642406 |
SEN2015-01 |
SERAPHINA |
December 2015 |
December 2018 |
|
December 30, 2015 |
October 10, 2016 |
|
- Aalen Brustzentrum
Aalen, Baden-Württemberg, Germany - Universitätsklinikum Freiburg
Freiburg, Baden-Württemberg, Germany - NCT Heidelberg
Heidelberg, Baden-Württemberg, Germany - (and 68 more...)
|
| 34 |
NCT03429101 |
Recruiting |
A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer |
|
- Drug: Poziotinib
- Drug: T-DM1
|
Interventional |
Phase 1 |
- Spectrum Pharmaceuticals, Inc
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD)
- Objective Response Rate (ORR)
- Disease Control Rate (DCR)
- Progression-free Survival (PFS)
|
25 |
Female |
18 Years to 90 Years (Adult, Senior) |
NCT03429101 |
SPI-POZ-101 |
|
March 2018 |
February 2020 |
February 2021 |
February 12, 2018 |
March 9, 2018 |
|
- Pacific Cancer Medical Center, Inc.
Anaheim, California, United States
|
| 35 |
NCT01306045 |
Recruiting |
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies |
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell Lung
- Carcinoma, Thymic
|
- Drug: AZD6244
- Drug: MK-2206
- Drug: Lapatinib
- (and 3 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the feasibility of the use of tumor molecular profiling and targeted therapies in the treatment of NSCLC, SCLC, and Thymic Malignancies
- To estimate the response rate of molecular-profile directed treatments in NSCLC, SCLC, and Thymic Malignancies
|
600 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01306045 |
110096
11-C-0096 |
|
February 26, 2011 |
January 31, 2019 |
December 30, 2019 |
March 1, 2011 |
February 8, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 36 |
NCT00939523 |
Recruiting |
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy |
- Pituitary Adenomas
- Prolactinomas
|
|
Interventional |
Phase 2 |
- Cedars-Sinai Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary outcome in nonfunctioning adenomas: stabilization of tumor volume and mean tumor diameter on MRI. Stabilization is defined as < 2 mm change in any dimension. MRIs will be performed at baseline and at 3 and 6 months.
- Primary outcome in prolactinomas: normalization of prolactin levels. Prolactin levels will be measured at baseline and monthly.
- Secondary outcomes: measurement of pituitary hormones
- Secondary outcome: visual field testing
|
21 |
All |
18 Years and older (Adult, Senior) |
NCT00939523 |
18129 |
|
July 2009 |
December 2018 |
December 2019 |
July 15, 2009 |
January 26, 2018 |
|
- Cedars-Sinai Medical Center
Los Angeles, California, United States - Johns Hopkins University
Baltimore, Maryland, United States - Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 37 |
NCT02701907 |
Recruiting |
EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies |
|
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Other
|
- The primary endpoint is the rate of patients with tumors harboring a low level of genomic alteration (mutation, amplification or deletion) in genes (i.e. mutation, amplification, deletion) identified as causally implicated in cancer
- The secondary endpoint is the rate of tumors with low level of genomic alterations between the EXPRESS cohort and control cohorts of patients.
- Exploratory analyses will be performed to compare the profiles between the EXPRESS and the control cohorts of patients, to identify novel candidate somatic molecular profiles
|
264 |
All |
18 Years and older (Adult, Senior) |
NCT02701907 |
UC-0105/1508 |
EXPRESS |
February 2016 |
February 2019 |
August 2019 |
March 8, 2016 |
February 10, 2017 |
|
- Dr Laetitia STEFANI
Annecy, France
|
| 38 |
NCT03054363 |
Recruiting |
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer |
|
- Drug: Tucatinib in Combination with Palbociclib and Letrozole
|
Interventional |
Phase 1
Phase 2 |
- University of Colorado, Denver
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The number of patients in the Pase 1b part of the study with any adverse events (AE).
- The number of patients with progression-free survival (PFS)
- Identify the pharmacokinetic (PK) properties of tucatinib and palbociclib current RP2D.
|
40 |
Female |
18 Years to 100 Years (Adult, Senior) |
NCT03054363 |
16-1661.cc |
|
November 13, 2017 |
October 2018 |
October 2018 |
February 15, 2017 |
April 20, 2018 |
|
- University of Arizona
Tucson, Arizona, United States - University of Colorado Denver
Aurora, Colorado, United States - Northwestern University
Chicago, Illinois, United States - (and 3 more...)
|
| 39 |
NCT03145961 |
Recruiting |
A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients |
- Triple Negative Breast Cancer
|
|
Interventional |
Phase 2 |
- Institute of Cancer Research, United Kingdom
- National Institute for Health Research Biomedical Research Centre at the Royal Marsden / Institute of Cancer Research UK
- Merck Sharp & Dohme Ltd
- Institute of Cancer Research, United Kingdom
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Positive ctDNA detection by 12 months
- Positive ctDNA detection by 24 months
- Absence of detectable ctDNA or disease recurrence 12 months after commencing pembrolizumab
- (and 6 more...)
|
200 |
All |
16 Years and older (Child, Adult, Senior) |
NCT03145961 |
ICR-CTSU/2016/10058
2017-000508-92 |
c-TRAK-TN |
December 21, 2017 |
June 1, 2021 |
December 1, 2022 |
May 9, 2017 |
January 29, 2018 |
|
- Royal Marsden Hospital, Chelsea
Chelsea, London, United Kingdom - Royal Marsden Hospital, Sutton
Sutton, Surrey, United Kingdom - Queen Elizabeth Hospital
Birmingham, United Kingdom - (and 14 more...)
|
| 40 |
NCT03430024 |
Not yet recruiting |
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer |
|
- Other: Association of Myosin VI with oestrogen receptor
|
Observational |
|
- Maidstone & Tunbridge Wells NHS Trust
- University of Kent
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Gene expression of Myosin VI and oestrogen receptor targets in tumour tissue.
- Quantification of Myosin VI protein in tumour tissue.
- Localisation of Myosin VI on the tumour genome
- Comparison of nuclear Myosin VI and oestrogen receptor localisation between different breast cancer prognostic groups.
|
120 |
Female |
18 Years to 85 Years (Adult, Senior) |
NCT03430024 |
17/09/621_Myosin VI |
|
April 2018 |
April 2020 |
April 2020 |
February 12, 2018 |
February 12, 2018 |
|
|
| 41 |
NCT03219476 |
Recruiting |
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance |
- Breast Cancer
- Invasive Breast Cancer
|
- Drug: Anastrozole
- Drug: Letrozole
- Drug: Exemestane
- Drug: Tamoxifen
|
Interventional |
Phase 2 |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Protein expression will be quantified on slides, using optimized immunohistochemical protocols for planned study biomarkers.
- Ki-67 assessment specimens will be assessed by manual counting of stained tumor cells.
- Ki-67 assessment specimens will be assessed by quantitative immunohistochemistry.
- (and 2 more...)
|
39 |
Female |
18 Years and older (Adult, Senior) |
NCT03219476 |
PRO30178 |
|
February 5, 2017 |
December 1, 2019 |
December 1, 2020 |
July 17, 2017 |
February 12, 2018 |
|
- Froedtert Hospital
Milwaukee, Wisconsin, United States
|
| 42 |
NCT02299999 |
Recruiting |
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer |
|
- Drug: AZD2014
- Drug: AZD4547
- Drug: AZD5363
- (and 16 more...)
|
Interventional |
Phase 2 |
- UNICANCER
- Fondation ARC
- AstraZeneca
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm
- progression-free survival in patients treated with anti-PDL1 antibody (MEDI4736) compared to standard maintenance therapy arm
- overall survival in each substudy
- (and 4 more...)
|
1460 |
All |
18 Years and older (Adult, Senior) |
NCT02299999 |
UC-0105/1304
2013-001652-36 |
SAFIR02_Breast |
April 7, 2014 |
June 2019 |
June 2021 |
November 24, 2014 |
May 5, 2017 |
|
- Institut de Cancérologie de l'Ouest/Paul Papin
Angers, France - Institut Sainte-Catherine
Avignon, France - Institut Bergonié
Bordeaux, France - (and 18 more...)
|
| 43 |
NCT02130492 |
Recruiting |
A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG) |
- Radiosensitive Stage IV Solid and Hematological Tumors With High FDG Uptake Not Responding to Standard of Care
- Lung Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer, Pancreatic Cancer, Colon Cancer, Lymphomas, Sarcomas, Etc
|
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Serious and Non-Serious Adverse Events and Type of Serious and Non-Serious Adverse Events
- Efficacy Outcome Measure
|
6 |
All |
21 Years and older (Adult, Senior) |
NCT02130492 |
IRB# 13-382A |
|
May 2014 |
July 2019 |
July 2019 |
May 5, 2014 |
September 11, 2017 |
|
- North Shore LIJ Cancer Institute
Lake Success, New York, United States - NSLIJ Monter Cancer Institute
Lake Success, New York, United States
|
| 44 |
NCT01471106 |
Recruiting |
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer |
|
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Susan G. Komen Breast Cancer Foundation
- Bristol-Myers Squibb
- M.D. Anderson Cancer Center
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in Ki-67 in Breast Tissue of High-Risk Women
|
66 |
Female |
18 Years and older (Adult, Senior) |
NCT01471106 |
2010-0794
NCI-2012-00037
KG09 1020 |
|
January 2014 |
January 2019 |
January 2019 |
November 11, 2011 |
October 24, 2017 |
|
- Duke University
Durham, North Carolina, United States - University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 45 |
NCT02342158 |
Recruiting |
Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors |
|
- Procedure: biopsy or surgical sampling
- Other: blood sampling
|
Interventional |
Not Applicable |
- Institut Paoli-Calmettes
- Cancer Research Center of Marseille
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- proportion of screened patients in whom a molecular abnormality for which a targeted therapy exists
- Molecular Characterization of locally advanced and metastatic malignancies using next generation sequencing
- Full exome and transcriptome sequencingof locally advanced and metastatic tumours
- (and 3 more...)
|
460 |
All |
18 Years and older (Adult, Senior) |
NCT02342158 |
PERMED01-IPC 2014-003 |
PERMED01 |
November 2014 |
November 2017 |
November 2020 |
January 19, 2015 |
June 28, 2016 |
|
- Institut Paoli-Calmettes
Marseille, France
|
| 46 |
NCT02465060 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Bladder Carcinoma
- Breast Carcinoma
- (and 47 more...)
|
- Drug: Adavosertib
- Drug: Afatinib
- Drug: Binimetinib
- (and 21 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate, defined as the percentage of patients whose tumors have a complete or partial response to treatment
- Overall survival, evaluated specifically for each drug (or step)
- Progression free survival
- Time to progression
|
6452 |
All |
18 Years and older (Adult, Senior) |
NCT02465060 |
NCI-2015-00054
EAY131
U10CA180820
U24CA196172 |
|
August 12, 2015 |
June 30, 2022 |
|
June 8, 2015 |
April 24, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 1212 more...)
|
| 47 |
NCT03493854 |
Not yet recruiting
New |
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer |
|
- Drug: Cyclophosphamide
- Drug: Doxorubicin
- Drug: Docetaxel
- (and 8 more...)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Trough Serum Concentration (Ctrough) of Pertuzumab During Cycle 7
- Ctrough of Trastuzumab During Cycle 7
- Percentage of Participants with Total Pathological Complete Response (tpCR), According to Local Pathologist Assessment
- (and 9 more...)
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT03493854 |
WO40324
2017-004897-32 |
|
July 26, 2018 |
March 1, 2020 |
September 12, 2024 |
April 11, 2018 |
April 11, 2018 |
|
- Banner MD Anderson Cancer Center
Gilbert, Arizona, United States - Comprehensive Blood/Cancer Ctr
Bakersfield, California, United States - Marin Cancer Care Inc
Greenbrae, California, United States - (and 76 more...)
|
| 48 |
NCT01570998 |
Recruiting |
Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery |
- Stage IA Breast Cancer
- Stage IIA Breast Cancer
|
- Radiation: Intraoperative Radiation Therapy
- Other: Laboratory Biomarker Analysis
|
Interventional |
Not Applicable |
- University of California, San Francisco
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of local recurrence
|
750 |
Female |
45 Years and older (Adult, Senior) |
NCT01570998 |
117515
NCI-2017-00461
11-06843
P30CA082103 |
|
May 2012 |
December 2018 |
December 2023 |
April 4, 2012 |
October 26, 2017 |
|
- Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States - California Hospital Medical Center
Los Angeles, California, United States - UCSF Medical Center-Mount Zion
San Francisco, California, United States - (and 17 more...)
|
| 49 |
NCT02422498 |
Recruiting |
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy |
- Locally Recurrent/Metastatic Triple Negative Breast Cancer
|
- Radiation: external beam radiation therapy
- Drug: cisplatin
- Procedure: Biopsy of Target Tumor
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Cedars-Sinai Medical Center
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- response (RECIST 1.1 vs. PET Response Criteria (PRC) as measurement tools for treatment response)
|
54 |
Female |
18 Years and older (Adult, Senior) |
NCT02422498 |
15-032 |
|
April 2015 |
April 2019 |
April 2019 |
April 21, 2015 |
January 12, 2018 |
|
- Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States - (and 3 more...)
|
| 50 |
NCT02310711 |
Recruiting |
Multi-scale Modeling of Breast Conserving Therapy |
|
|
Observational |
|
- The Methodist Hospital System
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
15 |
Female |
30 Years to 80 Years (Adult, Senior) |
NCT02310711 |
Pro00006887
IRB0112-0007
BCTMM01 |
BCT |
May 2012 |
December 2017 |
December 2017 |
December 8, 2014 |
August 2, 2016 |
|
- Houston Methodist Hopsital
Houston, Texas, United States
|
Create an RSS feed from your search for:
Download the search results for: